Filter News
Area of Research
- (-) Neutron Science (5)
- Advanced Manufacturing (1)
- Biology and Environment (6)
- Clean Energy (6)
- Computer Science (1)
- Fusion and Fission (3)
- Fusion Energy (1)
- Isotope Development and Production (1)
- Materials (18)
- Materials Characterization (1)
- Materials Under Extremes (1)
- National Security (7)
- Nuclear Science and Technology (1)
- Quantum information Science (1)
- Supercomputing (19)
News Type
News Topics
- (-) Biomedical (1)
- (-) High-Performance Computing (1)
- (-) Materials Science (1)
- (-) Nuclear Energy (1)
- (-) Physics (1)
- 3-D Printing/Advanced Manufacturing (1)
- Big Data (1)
- Biology (1)
- Biotechnology (1)
- Coronavirus (1)
- Environment (1)
- Materials (2)
- Nanotechnology (1)
- Neutron Science (10)
- Sustainable Energy (1)
Media Contacts
The Department of Energy’s Office of Science has selected three ORNL research teams to receive funding through DOE’s new Biopreparedness Research Virtual Environment initiative.
Like most scientists, Chengping Chai is not content with the surface of things: He wants to probe beyond to learn what’s really going on. But in his case, he is literally building a map of the world beneath, using seismic and acoustic data that reveal when and where the earth moves.
ORNL has entered a strategic research partnership with the United Kingdom Atomic Energy Authority, or UKAEA, to investigate how different types of materials behave under the influence of high-energy neutron sources. The $4 million project is part of UKAEA's roadmap program, which aims to produce electricity from fusion.
An ORNL-led team's observation of certain crystalline ice phases challenges accepted theories about super-cooled water and non-crystalline ice. Their findings, reported in the journal Nature, will also lead to better understanding of ice and its various phases found on other planets, moons and elsewhere in space.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.